Table 2.
Risk factors for diffuse large B cell lymphoma.
| Clinical Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-Value | HR | 95% CI | p-Value | |
| Age, years | ||||||
| <65 | 1.00 | 1.00 | ||||
| ≥65 | 2.74 | 1.32–5.67 | 0.007 | 1.46 | 0.57–3.71 | 0.432 |
| Gender | ||||||
| Male | 1.00 | |||||
| Female | 0.78 | 0.38–1.59 | 0.489 | |||
| Performance status | ||||||
| ≤2 | 1.00 | |||||
| >2 | 2.17 | 0.76–6.22 | 0.150 | |||
| Stage | ||||||
| Limited (Stage: 1–2) | 1.00 | 1.00 | ||||
| Advanced (Stage: 3–4) | 6.58 | 2.00–21.66 | 0.002 | 5.00 | 1.36–18.35 | 0.015 |
| Bulky, n (%) | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 2.17 | 1.07–4.42 | 0.032 | 1.80 | 0.78–4.16 | 0.169 |
| R-IPI score | ||||||
| Non-poor risk (0–2) | 1.00 | 1.00 | ||||
| Poor risk (3–5) | 3.21 | 1.51–6.83 | 0.002 | 1.21 | 0.52–2.85 | 0.655 |
| CCI score | 1.35 | 1.13–1.60 | 0.001 | 1.30 | 1.03–1.63 | 0.025 |
| LDH (U/L) | 1.00 | 1.00–1.00 | 0.197 | |||
| Uric acid (mg/dL) | 1.13 | 1.02–1.25 | 0.019 | |||
| Maximal SUV (/1 h) | 1.09 | 1.02–1.17 | 0.016 | |||
| Double hit | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 2.63 | 1.16–5.93 | 0.020 | 1.62 | 0.65–4.06 | 0.300 |
| Double expresser | ||||||
| No | 1.00 | |||||
| Yes | 1.47 | 0.69–3.12 | 0.320 | |||
| Cell of origin | ||||||
| GCB | 1.00 | |||||
| Non-GCB | 1.11 | 0.51–2.42 | 0.800 | |||
Data analysis by the Cox proportional hazard model. HR: hazard ratio; CI: confidence interval; CCI: Charlson comorbidity index; LDH: lactate dehydrogenase; SUV: standardized uptake value; GCB: germinal center B-cell.